The FDA has approved a new subcutaneous formulation of Eisai and Biogen’s Alzheimer’s drug Leqembi, marking an incremental strategic advancement to compete with Eli Lilly’s Kisunla. This approval allows the drug to be injected under the skin, potentially broadening patient accessibility and improving administration convenience compared to existing formulations. The move reflects ongoing efforts in Alzheimer’s therapeutics to optimize delivery methods and enhance treatment adherence.